NNC0519-0130
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Novo Nordisk · Phase 2 · Recruiting · Enrollment 465
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Dosing scheme a: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme a: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme b: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme b: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme c: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme c: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme d: NNC0519-0130 | n/r | n/r | n/r | n/r |
| Dosing scheme d: Placebo | n/r | n/r | n/r | n/r |
| Dosing scheme e: Semaglutide | n/r | n/r | n/r | n/r |
Not shown
- Dosing scheme a: NNC0519-0130: endpoint not reported
- Dosing scheme a: Placebo: endpoint not reported
- Dosing scheme b: NNC0519-0130: endpoint not reported
- Dosing scheme b: Placebo: endpoint not reported
- Dosing scheme c: NNC0519-0130: endpoint not reported
- Dosing scheme c: Placebo: endpoint not reported
- Dosing scheme d: NNC0519-0130: endpoint not reported
- Dosing scheme d: Placebo: endpoint not reported
- Dosing scheme e: Semaglutide: endpoint not reported